|
FDA Reorganizes Regulatory Affairs Office to Respond to Drug Industry Globalization
The FDA is planning to reorganize its Office of Regulatory Affairs (ORA), including creating new offices and reorganizing others, as it takes steps to dissolve cumbersome domestic and international distinctions and to keep up with increasingly global operations.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives